GlassScriptPhysician profile
Tseday Samuel
NPI 1528132636
$3,904.16
in general payments reported to CMS, 2019-2025
15 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.74 · 2022: $1,257 · 2023: $1,171 · 2024: $1,098 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Travel and Lodging: $35.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.18 |
| Travel and Lodging | $35.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,107.22 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $626.19 | 2022-2023 | Optimizer |
| Amgen INC. | $493.60 | 2022-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $427.41 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $387.57 | 2022-2024 | Assure Wcd |
| Scpharmaceuticals INC. | $171.39 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $138.33 | 2024 | Uptravi, Opsumit |
| Silk Road Medical, INC. | $130.38 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abiomed | $121.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $83.85 | 2023 | Farxiga |
| Boston Scientific Corporation | $66.56 | 2025 | Enroute Transcarotid Neuroprotection System, General - Pain Management |
| Pfizer INC. | $46.11 | 2022 | |
| Merck Sharp & Dohme LLC | $43.37 | 2023-2024 | Verquvo, Steglatro |
| Novartis Pharmaceuticals Corporation | $38.43 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tseday Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.